-transparent.png){kind=logo}
Cytotoxic chemotherapy and interferon have shown synergistic antitumor activity in vitro. The purpose of this study was to determine the maximally tolerated dose of doxorubicin given every 3 weeks, in patients receiving recombinant alpha 2-interferon [10 X 10(6) IU/m2 s.c. three times per week (Monday, Wednesday, and Friday)] during the first 2 weeks of each cycle of doxorubicin. Fourteen patients received a total of 41 cycles. Hematological toxicity was dose limiting with granulocytopenia (total granulocyte count, less than 1000) occurring in 50% of patients treated with doxorubicin at 40 mg/m2 and in 25% of patients treated with doxorubicin at 30 mg/m2. Nonhematological toxicities included a flu-like syndrome, alopecia, nausea, vomiting, diarrhea, and transient mild increases in liver function tests. A partial response was seen in one patient with metastatic squamous cell carcinoma of the skin and in another patient with metastatic adenocarcinoma of the pancreas. Concomitant administration of recombinant alpha 2-interferon given on this schedule limits the amount of doxorubicin that can be administered. However, the responses noted in this study are encouraging enough to warrant additional studies of doxorubicin plus recombinant alpha 2-interferon.
G A Sarosy, and
T D Brown, and
D D Von Hoff, and
R J Spiegel, and
J P Golando, and
K L Beougher, and
J G Kuhn, and
D L Kisner
August 1991,
Investigational new drugs,
G A Sarosy, and
T D Brown, and
D D Von Hoff, and
R J Spiegel, and
J P Golando, and
K L Beougher, and
J G Kuhn, and
D L Kisner
December 2006,
Cancer,
G A Sarosy, and
T D Brown, and
D D Von Hoff, and
R J Spiegel, and
J P Golando, and
K L Beougher, and
J G Kuhn, and
D L Kisner
October 2010,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G A Sarosy, and
T D Brown, and
D D Von Hoff, and
R J Spiegel, and
J P Golando, and
K L Beougher, and
J G Kuhn, and
D L Kisner
October 1991,
Cancer,
G A Sarosy, and
T D Brown, and
D D Von Hoff, and
R J Spiegel, and
J P Golando, and
K L Beougher, and
J G Kuhn, and
D L Kisner
May 2009,
Cancer chemotherapy and pharmacology,
G A Sarosy, and
T D Brown, and
D D Von Hoff, and
R J Spiegel, and
J P Golando, and
K L Beougher, and
J G Kuhn, and
D L Kisner
January 2009,
Chemotherapy,
G A Sarosy, and
T D Brown, and
D D Von Hoff, and
R J Spiegel, and
J P Golando, and
K L Beougher, and
J G Kuhn, and
D L Kisner
January 2005,
Oncology,
G A Sarosy, and
T D Brown, and
D D Von Hoff, and
R J Spiegel, and
J P Golando, and
K L Beougher, and
J G Kuhn, and
D L Kisner
May 1988,
Cancer research,
G A Sarosy, and
T D Brown, and
D D Von Hoff, and
R J Spiegel, and
J P Golando, and
K L Beougher, and
J G Kuhn, and
D L Kisner
August 1993,
Cancer research,
G A Sarosy, and
T D Brown, and
D D Von Hoff, and
R J Spiegel, and
J P Golando, and
K L Beougher, and
J G Kuhn, and
D L Kisner
February 2024,
Journal for immunotherapy of cancer,
